Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atropine - Vyluma

Next Previous
Search
Drug Profile

Atropine - Vyluma

Alternative Names: Atropine - Nevakar; NVK-002

Latest Information Update: 05 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nevakar
  • Developer Nevakar; Zhaoke (Hong Kong) Ophthalmology Pharmaceutical
  • Class Alkaloids; Antidotes; Cardiovascular therapies; Eye disorder therapies; Small molecules; Tropanes
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Myopia

Most Recent Events

  • 29 Jan 2025 The National Medical Products Administration (NMPA) of China accepts the regulatory application for atropine for Myopia for review
  • 18 Jun 2024 Vyluma announces intention to submit response to address US FDA’s questions in the third quarter of 2024
  • 04 Jun 2024 Vyluma receives complete response letter from the FDA for Atropine in Myopia prior to June 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top